Faculty




Andrew J. Cutler, MD


Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY


Dr. Andrew J. Cutler attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology.  He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD.  Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago.  He has been Board Certified in both Internal Medicine and Psychiatry.

Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.  

Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings.  He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards.  He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations.  He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.

Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association.  He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media. 

read more +




Joseph F. Goldberg, MD


Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY

Private Practice, Norwalk, CT


Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient.

Dr. Goldberg has published over 180 original research publications in major psychiatric journals as well as 3 books on topics related to mood disorders, focusing on the use of anticonvulsant mood stabilizers and atypical antipsychotics, safety risks with antidepressants in bipolar disorder, management of drug side effects, features related to rapid cycling bipolar disorder, suicide risk in bipolar disorder, cognitive dysfunction in bipolar disorder, pharmacogenetics in bipolar disorder, comorbid psychiatric disorders in bipolar disorder, and the long-term functional course and outcome of bipolar disorder and depression. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences, such as the American Psychiatric Association, the Society of Biological Psychiatry, the American Society for Clinical Psychopharmacology, the American College of Neuropsychopharmacology, the European College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum, the International Society for Affective Disorders, and the International Society for Bipolar Disorders.   

read more +




David W. Goodman, MD, FAPA


Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY

Private Practice, Norwalk, CT


Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology. 

read more +




Roger S. McIntyre, MD, FRCPC


Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada

Professor, Guangzhou Medical University, Guangzhou, China

Professor, College of Medicine, Korea University, Seoul, Republic of Korea,

Professor, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA

Professor, University of California School of Medicine, Riverside, California, USA

Chairman and Executive Director, Brain and Cognition Discovery Foundation (BCDF), Toronto, Canada

Director and Chair, Scientific Advisory Board, Depression and Bipolar Support Alliance (DBSA), Chicago, Illinois, USA


Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. 

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.    

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. 

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

read more +




Jeffrey R. Strawn, MD


Associate Professor, Departments of Pediatrics and of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, Cincinnati, OH


Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents. His examination of cortical thickness in adolescents with anxiety, revealed abnormalities in cortical thickness in an ensemble of regions responsible for fear learning, fear extinction, reflective functioning (e.g., mentalization), and regulation of the amygdala. Additionally, gray matter volumes in youth with anxiety disorders are greater in the dorsal anterior cingulate and decreased in the ventrolateral prefrontal cortex), cuneus/precuneus, as well as decreased amygdala gray matter volumes in the amygdala which is consistent with his functional MRI data suggesting increased activation in youth with anxiety disorders, relative to healthy comparison subjects, during a continuous processing task with emotional and neutral distractors. Additionally, from a neurochemistry standpoint, he has demonstrated that glutamatergic tone in the anterior cingulate cortex is directly linked with anxiety symptom severity in youth with anxiety. These studies suggest that anxiety disorders are associated with structural, functional and neurochemical abnormalities with prefrontal-amygdala circuitry. By providing evidence of these structural, functional and neurochemical abnormalities, this body of work has propelled additional studies of these structures in youth who are at risk for developing anxiety disorders and in studies which have allowed the integration of psychopharmacologic treatment studies with neuroimaging evaluations of anxious youth.

In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. As an example, with his collaborators, they demonstrated the efficacy of duloxetine in a double-blind placebo controlled trial of duloxetine which culminated in a FDA indication for duloxetine in children and adolescents with GAD (age 7-17).

read more +